Chesley Taft & Associates LLC Grows Position in Edwards Lifesciences Corp (EW)

Chesley Taft & Associates LLC increased its position in Edwards Lifesciences Corp (NYSE:EW) by 4.1% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 22,662 shares of the medical research company’s stock after acquiring an additional 900 shares during the period. Chesley Taft & Associates LLC’s holdings in Edwards Lifesciences were worth $3,945,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Bank Hapoalim BM lifted its stake in Edwards Lifesciences by 10.4% in the 2nd quarter. Bank Hapoalim BM now owns 3,730 shares of the medical research company’s stock valued at $543,000 after buying an additional 350 shares in the last quarter. Janney Montgomery Scott LLC lifted its stake in Edwards Lifesciences by 2.2% in the 2nd quarter. Janney Montgomery Scott LLC now owns 16,336 shares of the medical research company’s stock valued at $2,378,000 after buying an additional 355 shares in the last quarter. Wendell David Associates Inc. lifted its stake in Edwards Lifesciences by 4.0% in the 2nd quarter. Wendell David Associates Inc. now owns 9,548 shares of the medical research company’s stock valued at $1,390,000 after buying an additional 363 shares in the last quarter. Park Avenue Securities LLC lifted its stake in Edwards Lifesciences by 9.6% in the 2nd quarter. Park Avenue Securities LLC now owns 4,411 shares of the medical research company’s stock valued at $645,000 after buying an additional 387 shares in the last quarter. Finally, Tyers Asset Management LLC lifted its stake in Edwards Lifesciences by 6.1% in the 2nd quarter. Tyers Asset Management LLC now owns 6,832 shares of the medical research company’s stock valued at $995,000 after buying an additional 392 shares in the last quarter. Institutional investors and hedge funds own 82.10% of the company’s stock.

In related news, VP Huimin Wang sold 3,800 shares of the stock in a transaction on Monday, August 6th. The stock was sold at an average price of $144.99, for a total value of $550,962.00. Following the completion of the sale, the vice president now directly owns 88,483 shares in the company, valued at approximately $12,829,150.17. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO Scott B. Ullem sold 25,036 shares of the stock in a transaction on Wednesday, September 5th. The shares were sold at an average price of $140.04, for a total value of $3,506,041.44. Following the completion of the sale, the chief financial officer now owns 41,019 shares of the company’s stock, valued at $5,744,300.76. The disclosure for this sale can be found here. Insiders sold a total of 158,811 shares of company stock worth $22,738,863 over the last ninety days. Corporate insiders own 1.84% of the company’s stock.

A number of research analysts have weighed in on the company. Morgan Stanley increased their price target on Edwards Lifesciences from $150.00 to $157.00 and gave the stock an “overweight” rating in a research note on Thursday. Zacks Investment Research raised Edwards Lifesciences from a “hold” rating to a “buy” rating and set a $165.00 price target on the stock in a research note on Saturday, July 14th. BMO Capital Markets increased their price target on Edwards Lifesciences to $162.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 10th. SunTrust Banks reduced their price target on Edwards Lifesciences to $170.00 and set a “buy” rating on the stock in a research note on Friday, August 10th. Finally, Sanford C. Bernstein assumed coverage on Edwards Lifesciences in a research note on Wednesday, June 27th. They set a “market perform” rating and a $165.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and fifteen have assigned a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $155.30.

Shares of EW traded up $3.81 during trading hours on Friday, hitting $143.58. The stock had a trading volume of 96,655 shares, compared to its average volume of 1,371,624. The company has a current ratio of 1.86, a quick ratio of 1.47 and a debt-to-equity ratio of 0.19. The firm has a market capitalization of $36.45 billion, a P/E ratio of 37.50, a price-to-earnings-growth ratio of 2.41 and a beta of 0.56. Edwards Lifesciences Corp has a 12-month low of $100.20 and a 12-month high of $175.00.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, July 26th. The medical research company reported $1.24 earnings per share for the quarter, topping the consensus estimate of $1.13 by $0.11. The business had revenue of $972.00 million for the quarter, compared to analyst estimates of $968.32 million. Edwards Lifesciences had a return on equity of 29.11% and a net margin of 19.59%. The business’s quarterly revenue was up 10.0% on a year-over-year basis. During the same period last year, the company posted $1.08 EPS. Sell-side analysts predict that Edwards Lifesciences Corp will post 4.67 earnings per share for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves.

Read More: Find a Trading Strategy That Works

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply